|
|
||||||||
AFIP ARCHIVES |
1 From the Departments of Radiologic Pathology (P.J.W.) and GYN and Breast Pathology (J.S.S.), Armed Forces Institute of Pathology, 14th St at Alaska Ave, Bldg 54, Rm M-121, Washington, DC 20306-6000; and the Department of Diagnostic Radiology, University of Maryland Medical System, Baltimore (K.H.). Received July 31, 2003; revision requested September 10 and received September 30; accepted October 1. All authors have no financial relationships to disclose. Address correspondence to P.J.W. (e-mail: woodwardp@afip.osd.mil).
Ovarian cancer is the deadliest gynecologic malignancy, with approximately 70% of patients having peritoneal involvement at the time of diagnosis. It spreads predominantly by direct invasion and intraperitoneal dissemination. The staging system is surgically based, with stage I disease being limited to one or both ovaries. In stage II disease, there is extraovarian spread of tumor, but it does not extend beyond the pelvis. Stages III and IV disease are considered advanced, with stage III ovarian cancer including diffuse peritoneal disease involving the upper abdomen and stage IV disease having distant metastases including hepatic lesions. Common sites of intraperitoneal seeding include the omentum, paracolic gutters, liver capsule, and diaphragm. Thickening, nodularity, and enhancement are all signs of peritoneal involvement. Although computed tomography is the most common imaging modality used to stage ovarian cancer, magnetic resonance imaging has been shown to be equally accurate. Currently, however, no imaging modality allows microscopic spread of disease to be ruled out, and a full staging laparotomy is always required. Early ovarian cancer is treated with comprehensive staging laparotomy, whereas advanced but operable disease is treated with primary cytoreductive surgery (debulking) followed by adjuvant chemotherapy. Patients with unresectable disease may benefit from neoadjuvant (preoperative) chemotherapy before debulking.
Index Terms: Ovary, CT, 852.12112 Ovary, MR, 852.121415 Ovary, neoplasms, 852.323
This article has been cited by other articles:
![]() |
A. N. Viswanathan, B. M. Buttin, and A. M. Kennedy Oncodiagnosis Panel: 2006: Ovarian, Cervical, and Endometrial Cancer RadioGraphics, January 1, 2008; 28(1): 289 - 307. [Full Text] [PDF] |
||||
![]() |
G. E. Pastore, C. R. Lamb, and V. Lipscomb Comparison of the Results of Abdominal Ultrasonography and Exploratory Laparotomy in the Dog and Cat J. Am. Anim. Hosp. Assoc., September 1, 2007; 43(5): 264 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Yarram, H. V. Nghiem, E. Higgins, G. Fox, B. Nan, and I. R. Francis Evaluation of Imaging-Guided Core Biopsy of Pelvic Masses Am. J. Roentgenol., May 1, 2007; 188(5): 1208 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
M V Pakkal and M Balogun Imaging of ovarian cancer Imaging, August 1, 2006; 18(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Burkholz, B. P. Wood, and C. Zuppan Best Cases from the AFIP: Borderline Papillary Serous Tumor of the Right Ovary RadioGraphics, November 1, 2005; 25(6): 1689 - 1692. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOGRAPHICS | RADIOLOGY | RSNA JOURNALS ONLINE |